Literature DB >> 17559366

Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis.

Hideyuki Hyogo1, Sho-ichi Yamagishi, Keiko Iwamoto, Koji Arihiro, Masayoshi Takeuchi, Takashi Sato, Hidenori Ochi, Michihiro Nonaka, Yoshitaka Nabeshima, Motoki Inoue, Tomokazu Ishitobi, Kazuaki Chayama, Susumu Tazuma.   

Abstract

BACKGROUND AND AIM: Advanced glycation end products (AGE), senescent macroprotein derivatives formed at an accelerated rate in diabetes, play important roles in the pathogenesis of diabetic vascular complications. Recently, AGE have also been found to be involved in insulin resistance. Although non-alcoholic steatohepatitis (NASH) is generally considered a hepatic manifestation of insulin resistance, there are no reports showing the link of AGE to NASH. The aim of this study was to evaluate the clinical significance of AGE in patients with NASH.
METHODS: Glyceraldehyde-derived AGE levels were assayed from serum obtained from 106 patients: 66 with NASH, 10 with simple steatosis, and 30 controls.
RESULTS: Serum glyceraldehyde-derived AGE levels (U/mL) were significantly elevated in NASH patients (9.78 +/- 3.73) compared with simple steatosis (7.17 +/- 2.28, P = 0.018) or healthy controls (6.96 +/- 2.36, P = 0.003). Moreover, these were inversely correlated with adiponectin, an adipocytokine with insulin-sensitizing and anti-inflammatory properties. In addition, immunohistochemistry of glyceraldehyde-derived AGE showed intense staining in the livers of NASH patients.
CONCLUSION: The present data suggest that the sustained increase of glyceraldehyde-derived AGE could at least in part contribute to the pathogenesis of NASH. The serum glyceraldehyde-derived AGE level may be a useful biomarker for discriminating NASH from simple steatosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17559366     DOI: 10.1111/j.1440-1746.2007.04943.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  62 in total

1.  MK615 decreases RAGE expression and inhibits TAGE-induced proliferation in hepatocellular carcinoma cells.

Authors:  Yuhki Sakuraoka; Tokihiko Sawada; Toshie Okada; Takayuki Shiraki; Yoshikazu Miura; Katsuya Hiraishi; Tatsushi Ohsawa; Masakazu Adachi; Jun-ichi Takino; Masayoshi Takeuchi; Keiichi Kubota
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

2.  Elevation of Serum Levels of Advanced Glycation End Products in Patients With Non-B or Non-C Hepatocellular Carcinoma.

Authors:  Hiromi Kan; Sho-ichi Yamagishi; Ayako Ojima; Kei Fukami; Seiji Ueda; Masayoshi Takeuchi; Hideyuki Hyogo; Hiroshi Aikata; Kazuaki Chayama
Journal:  J Clin Lab Anal       Date:  2014-09-23       Impact factor: 2.352

Review 3.  Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma.

Authors:  Jun-Ichi Takino; Kentaro Nagamine; Takamitsu Hori; Akiko Sakasai-Sakai; Masayoshi Takeuchi
Journal:  World J Hepatol       Date:  2015-10-18

4.  In vitro identification of nonalcoholic fatty liver disease-related protein hnRNPM.

Authors:  Jun-ichi Takino; Kentaro Nagamine; Masayoshi Takeuchi; Takamitsu Hori
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

5.  Role of the receptor for advanced glycation end products in hepatic fibrosis.

Authors:  Christina Lohwasser; Daniel Neureiter; Yury Popov; Michael Bauer; Detlef Schuppan
Journal:  World J Gastroenterol       Date:  2009-12-14       Impact factor: 5.742

6.  Soluble receptor for advanced glycation end products and risk of liver cancer.

Authors:  Kristin A Moy; Li Jiao; Neal D Freedman; Stephanie J Weinstein; Rashmi Sinha; Jarmo Virtamo; Demetrius Albanes; Rachael Z Stolzenberg-Solomon
Journal:  Hepatology       Date:  2013-05-14       Impact factor: 17.425

7.  Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells.

Authors:  Keiko Iwamoto; Keishi Kanno; Hideyuki Hyogo; Sho-Ichi Yamagishi; Masayoshi Takeuchi; Susumu Tazuma; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2008-05-06       Impact factor: 7.527

8.  Risk factors and mechanisms of non-alcoholic steatohepatitis.

Authors:  Chantal A Rivera
Journal:  Pathophysiology       Date:  2008-07-29

9.  The formation of intracellular glyceraldehyde-derived advanced glycation end-products and cytotoxicity.

Authors:  Jun-ichi Takino; Yuka Kobayashi; Masayoshi Takeuchi
Journal:  J Gastroenterol       Date:  2010-01-19       Impact factor: 7.527

10.  Advanced glycation endproducts induce fibrogenic activity in nonalcoholic steatohepatitis by modulating TNF-α-converting enzyme activity in mice.

Authors:  Joy X Jiang; Xiangling Chen; Hiroo Fukada; Nobuko Serizawa; Sridevi Devaraj; Natalie J Török
Journal:  Hepatology       Date:  2013-08-06       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.